Drugs / PEPTIDE B27PD
PEPTIDE B27PD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01195948 | Aug 2010 → Nov 2013 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEPTIDE B27PD | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297903 ↗ |
| Known as | Alnedlsswtaadt | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297903 ↗ |
| Known as | Amino acids 125-138 of hla-b | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297903 ↗ |
| Known as | B27PD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195948 ↗ |
| Known as | Optiquel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297903 ↗ |
| Modality | Peptide | “B27PD, a small protein fragment” NCT01195948 ↗ |
| Route | Oral | “take the capsule orally three times per week” NCT01195948 ↗ |